Alexander Eggermont

Active 1992–2026

86
Papers
27,720
Citations
75
h-index
83
i10-index

Citations

Citations per year for Alexander Eggermont1985: 1 citations1994: 3 citations1995: 3 citations1997: 2 citations1999: 7 citations2000: 16 citations2001: 11 citations2002: 14 citations2003: 21 citations2004: 18 citations2005: 36 citations2006: 19 citations2007: 26 citations2008: 21 citations2009: 28 citations2010: 37 citations2011: 45 citations2012: 122 citations2013: 214 citations2014: 260 citations2015: 336 citations2016: 339 citations2017: 387 citations2018: 575 citations2019: 1,297 citations2020: 1,725 citations2021: 1,710 citations2022: 1,527 citations2023: 1,200 citations2024: 1,577 citations2025: 898 citations2026: 41 citations1986–1993: no citations, so these years are not shown1996: no citations, so this year is not shown1998: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,318 citing papers, 20.5% of this breakdownChina: 2,891 citing papers, 17.9% of this breakdownFrance: 914 citing papers, 5.7% of this breakdownItaly: 867 citing papers, 5.4% of this breakdownUnited Kingdom: 757 citing papers, 4.7% of this breakdownGermany: 697 citing papers, 4.3% of this breakdownCanada: 484 citing papers, 3% of this breakdownNetherlands: 445 citing papers, 2.7% of this breakdownAustralia: 432 citing papers, 2.7% of this breakdownSpain: 399 citing papers, 2.5% of this breakdownJapan: 369 citing papers, 2.3% of this breakdownIndia: 307 citing papers, 1.9% of this breakdown
0%20.5%Other 26.4%

Fields

  • Medicine41.3%
  • Biochemistry, Genetics and Molecular Biology36.7%
  • Immunology and Microbiology14.5%
  • Engineering2.1%
  • Materials Science1.2%
  • Neuroscience0.9%
  • Other3.3%

Topics

  • Cancer Immunotherapy and Biomarkers10.1%
  • Gut microbiota and health7.8%
  • Immunotherapy and Immune Responses5.9%
  • Immune Cell Function and Interaction3.6%
  • CAR-T cell therapy research3%
  • Immune cells in cancer2.9%
  • Other66.7%

Coauthors

All papers

Open in search
  1. Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Benoît Quinquis, Nicolas Pons, Bernhard Ryffel, Véronique Minard-Colin, Patrick Gonin, Jean‐Charles Soria, Éric Deutsch, Yohann Loriot, François Ghiringhelli, Gérard Zalcman, François Goldwasser, Bernard Escudier, Matthew D. Hellmann, Alexander Eggermont, Didier Raoult, Laurence Albigès, Guido Kroemer, Laurence Zitvogel - Science 2017 cited by 5,594

  2. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Caroline Robert, Christina Mateus, Guido Kroemer, Didier Raoult, Ivo G. Boneca, Franck Carbonnel, Mathias Chamaillard, Laurence Zitvogel - Science 2015 cited by 3,456

  3. Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy

    Authors: , , , , , - Annals of Oncology 2016 cited by 1,372

  4. Enterococcus hirae and Barnesiella intestinihominis Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Philip Rosenstiel, Didier Raoult, Vincent Cattoir, Ivo G. Boneca, Mathias Chamaillard, Laurence Zitvogel - Immunity 2016 cited by 854

  5. Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - OncoImmunology 2015 cited by 782

  6. Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Vichnou Poirier-Colame, Suzette Delaloge, Frédérique Penault‐Llorca, Sylvain Ladoire, Laurent Arnould, Joanna Cyrta, Marie-Charlotte Dessoliers, Alexander Eggermont, Marco E. Bianchi, Mikaël J. Pittet, Camilla Engblom, Christina Pfirschke, Xavier Préville, Gilles Uzé, Robert D. Schreiber, Melvyn T. Chow, Mark J. Smyth, Enrico Proietti, Fabrice André, Guido Kroemer, Laurence Zitvogel - Nature Medicine 2014 cited by 1,031

  7. Cross-reactivity between tumor MHC class I–restricted antigens and an enterococcal bacteriophage

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Edoardo Pasolli, Nicola Segata, Carlos López-Otı́n, Zoltán Szállási, Fabrice André, Valerio Iebba, Valentin Quiniou, David Klatzmann, Jacques Bou Khalil, S. Khelaifia, Didier Raoult, Laurence Albigès, Bernard Escudier, Alexander Eggermont, Fathia Mami‐Chouaib, Paola Nisticò, François Ghiringhelli, Bertrand Routy, Nathalie Labarrière, Vincent Cattoir, Guido Kroemer, Laurence Zitvogel - Science 2020 cited by 384

  8. Dendritic cell–derived exosomes for cancer therapy

    Authors: , , , , , , - Journal of Clinical Investigation 2016 cited by 613

  9. Global cancer surgery: delivering safe, affordable, and timely cancer surgery

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Luiz Antônio Santini, Shailesh V. Shrikhande, Mark G. Shrime, Robert Thomas, Audrey Tieko Tsunoda, Cornelis J.�H. van de Velde, Umberto Veronesi, D. K. Vijaykumar, David Watters, Shan Wang, Yi‐Long Wu, Moez Zeiton, Arnie Purushotham - The Lancet Oncology 2015 cited by 685

  10. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Caroline Robert, Alex Menzies, Thierry Lesimple, Michele Maio, Gerald P. Linette, Michael P. Brown, Peter Hersey, Inge Marie Svane, Laurent Mortier, Jacob Schachter, Catherine Barrow, Ragini R. Kudchadkar, Xinni Song, Caroline Dutriaux, Pietro Quaglino, Friedegund Meier, Paola Queirolo, Daniil Stroyakovskiy, Lars Bastholt, B. Guillot, Claus Garbe, Pablo L. Ortiz‐Romero, Florent Grange, Peter Mohr, Alain P. Algazi, Oliver Bechter, Micaela Hernberg, Jean‐Philippe Arnault, Philippe Saïag, Carmen Loquai, Frank Meiß, Jan‐Christoph Simon, Gil Bar‐Sela, Vanna Chiarion‐Sileni, Bernard M. Fitzharris, Mike McCrystal, Phillip Parente, Jean‐François Baurain, P. Combemale, Célèste Lebbé, Axel Hauschild, Naoya Yamazaki, Reinhard Dummer, Mohammed Milhem, Marcin Dzienis, John Walker, L. Geoffrois, M.‐T. Leccia, Lutz Kretschmer, Daniel Hendler, Michal Lotem, Andrzej Maćkiewicz, Lidija Kandolf Sekulović, Elaine Dunwoodie, Christoph Höeller, L. Machet, Jessica C. Hassel, Geke A.P. Hospers, Maria-Jose Passos, Max Levin, Martin Fehr, Philippa Corrie, Ashita Waterston, Sigrun Hallmeyer, Henrik Schmidt, V. Descamps, J.‐P. Lacour, Carola Berking, Felix Kiecker, Pier Francesco Ferrucci and 32 more - The Lancet Oncology 2021 cited by 389

  11. Diagnosis and treatment of basal cell carcinoma: European consensus–based interdisciplinary guidelines

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - European Journal of Cancer 2019 cited by 590

  12. Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Vincenzo Bronte, Jennifer A. Wargo, Laurence Zitvogel - Cell Research 2019 cited by 248

  13. Chemotherapy-induced ileal crypt apoptosis and the ileal microbiome shape immunosurveillance and prognosis of proximal colon cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jean‐Yves Scoazec, Peggy Dartigues, Antoine Hollebecque, David Malka, Franck Pagès, Jérôme Galon, Ivo G. Boneca, Patricia Lepage, Bernard Ryffel, Didier Raoult, Alexander Eggermont, Tom Vanden Berghe, François Ghiringhelli, Peter Vandenabeele, Guido Kroemer, Laurence Zitvogel - Nature Medicine 2020 cited by 196

  14. Trial watch: IDO inhibitors in cancer therapy

    Authors: , , , , , , , , , - OncoImmunology 2014 cited by 325

  15. Classification of current anticancer immunotherapies

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jérôme Galon, Abhishek D. Garg, François Ghiringhelli, Giuseppe Giaccone, Eli Gilboa, Sacha Gnjatic, Axel Hoos, Anne Hosmalin, Dirk Jäger, Paweł Kaliński, Klas Kärre, Oliver Kepp, Rolf Kiessling, John M. Kirkwood, Eva Klein, Alexander Knuth, Claire E. Lewis, Roland Liblau, Michael T. Lotze, Enrico Lugli, J P Mach, Fabrizio Mattei, Domenico Mavilio, Ignacio Melero, Cornelis J.M. Melief, Elizabeth A. Mittendorf, Lorenzo Moretta, Adekunke Odunsi, Hideho Okada, A. Karolina Palucka, Marcus E. Peter, Kenneth J. Pienta, Angel Porgador, George C. Prendergast, Gabriel A. Rabinovich, Nicholas P. Restifo, Naiyer A. Rizvi, Catherine Sautès‐Fridman, Hans Schreiber, Barbara Seliger, Hiroshi Shiku, Bruno Silva‐Santos, Mark J. Smyth, Daniel E. Speiser, Radek Špíšek, Pramod K. Srivastava, James E. Talmadge, Éric Tartour, Sjoerd H. van der Burg, Benoı̂t J. Van den Eynde, Richard G. Vile, Hermann Wagner, Jeffrey S. Weber, Theresa L. Whiteside, Jedd D. Wolchok, Laurence Zitvogel, Weiping Zou, Guido Kroemer - Oncotarget 2014 cited by 470

  16. Delivering affordable cancer care in high-income countries

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Paul Catchpole, David Taylor, Jan Geißler, Nancy Brinker, David Meltzer, David Kerr, Matti Aapro - The Lancet Oncology 2011 cited by 714

  17. Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy

    Authors: , , , , , , , , , , , , , - OncoImmunology 2015 cited by 297

  18. Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy

    Authors: , , , , , , , , - OncoImmunology 2012 cited by 245

  19. Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Thierry de Baère, Lambros Tselikas, Éric Solary, Eric Angevin, Alexander Eggermont, Fabrice André, Christophe Massard, Ken A. Olaussen, Jean‐Charles Soria, Benjamin Besse, Luc Friboulet - Clinical Cancer Research 2019 cited by 167

  20. Influence of microbiota-associated metabolic reprogramming on clinical outcome in patients with melanoma from the randomized adjuvant dendritic cell-based MIND-DC trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Nature Communications 2024 cited by 29

  21. Rare missense variants in POT1 predispose to familial cutaneous malignant melanoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Haritha Vallabhaneni, Weihang Chai, Paola Minghetti, Cristina Pellegrini, Sarangan Ravichandran, Alexander Eggermont, Mark Lathrop, Ketty Peris, Giovanna Bianchi‐Scarrà, G Landi, Sharon A. Savage, Joshua N. Sampson, Ji He, Meredith Yeager, Lynn R. Goldin, Florence Démenais, Stephen J. Chanock, Margaret A. Tucker, Alisa M. Goldstein, Yie Liu, Maria Teresa Landi - Nature Genetics 2014 cited by 333

  22. Predictors of responses to immune checkpoint blockade in advanced melanoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Dirk Schadendorf, Ignacio Melero, Brigitte Dréno, Amir Khammari, Reinhard Dummer, Mitchell P. Levesque, Yoshinobu Koguchi, Lawrence Fong, Michal Lotem, Michal Baniyash, Henrik Schmidt, Inge Marie Svane, Guido Kroemer, Aurélien Marabelle, Stefan Michiels, Andréa Cavalcanti, Mark J. Smyth, Jeffrey S. Weber, Alexander Eggermont, Laurence Zitvogel - Nature Communications 2017 cited by 201

  23. Renal Cell Carcinoma Programmed Death-ligand 1, a New Direct Target of Hypoxia-inducible Factor-2 Alpha, is Regulated by von Hippel–Lindau Gene Mutation Status

    Authors: , , , , , , , , , , , , , , , , , , - European Urology 2015 cited by 176

  24. Prognostic value of patient-reported outcomes from international randomised clinical trials on cancer: a systematic review

    Authors: , , , , , , , , , , , , - The Lancet Oncology 2019 cited by 129